Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Return on Equity (2022 - 2026)

TriSalus Life Sciences has reported Return on Equity over the past 5 years, most recently at 0.03% for Q1 2026.

  • For Q1 2026, Return on Equity rose 2.0% year-over-year to 0.03%; the TTM value through Mar 2026 reached 0.03%, up 2.0%, while the annual FY2025 figure was 0.01%, 0.0% changed from the prior year.
  • Return on Equity for Q1 2026 was 0.03% at TriSalus Life Sciences, up from 0.01% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.06% in Q4 2023 and troughed at 0.0% in Q3 2022.
  • A 5-year average of 0.02% and a median of 0.01% in 2025 define the central range for Return on Equity.
  • Biggest five-year swings in Return on Equity: rose 6bps in 2023 and later fell -5bps in 2024.
  • Year by year, Return on Equity stood at 0.0% in 2022, then skyrocketed by 4016bps to 0.06% in 2023, then tumbled by -79bps to 0.01% in 2024, then dropped by 0bps to 0.01% in 2025, then soared by 100bps to 0.03% in 2026.
  • Business Quant data shows Return on Equity for TLSI at 0.03% in Q1 2026, 0.01% in Q4 2025, and 0.02% in Q3 2025.